Ultragenyx gets FDA nod for first Sanfilippo A gene therapy
Patients in the US with Sanfilippo syndrome type A have their first FDA-approved therapy, Ultragenyx Pharma's $3.9m one-shot gene therapy Fayuvi.
Newsletters and Deep Dive digital magazine
Patients in the US with Sanfilippo syndrome type A have their first FDA-approved therapy, Ultragenyx Pharma's $3.9m one-shot gene therapy Fayuvi.
Once a treatment becomes available to the public, protecting patient safety remains a priority throughout its time on the market.
Boehringer Ingelheim has launched a hub to help patient organisations gather and use patient experience data (PED) more effectively.
A report has concluded that the current regulatory framework in the UK is inadequate for healthcare AI, and makes 44 recommendations to set it right.
Some pharmacists in England can now prescribe drugs for acne, migraines, scabies, ear infections, and rhinitis under the Pharmacy First scheme.
Editor's Picks
Newsletters and Deep Dive
digital magazine